When researchers looked for the marker in patients, they were able to predict whether the patients had colon cancer with 95 percent accuracy, according to Ann M. Bode, PhD, section leader and professor at the institute. “This suggests that this compound TXA2 could be a target perhaps for treating colon cancer or preventing it,” she said to ABC 6 News. A larger study is needed to confirm this development.
More articles on gastroenterology:
Dr. Lyndon Hernandez: Uniting the voices in GI & demonstrating quality
ASGE STAR program to offer Barrett’s ablation course
EndoChoice releases FUSE portfolio’s slim colonoscope
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.